OK HB1074

Creates the "Right to Try Act" allowing terminally ill patients to access investigational drugs, biological products, or devices that have completed phase one FDA clinical trials but are not yet fully approved

Eligible patients must have a physician-attested terminal illness, have considered all FDA-approved treatments, be unable to access a clinical trial within 100 miles or not accepted within 1 week, and provide written informed consent

Manufacturers may provide investigational treatments at no cost or charge manufacturing costs; health insurers may but are not required to cover these treatments

Prohibits licensing boards from taking action against health care providers solely for recommending investigational treatments consistent with medical standards of care

Protects manufacturers and care providers from private lawsuits for harm resulting from investigational treatments, provided they act in good faith and exercise reasonable care